Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04661826 | ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder. | completed | Phase 2 | 60 | Fidia Farmaceutici s.p.a.INDUSTRY | 3 | Dec 10, 2020 | clinicaltrials |
| NCT02788201 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2020 | clinicaltrials |
| NCT00003930 |
| Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer |
| completed |
| Phase 1 / Phase 2 |
| 84 |
| Radiation Therapy Oncology GroupNETWORK |
| 2 |
| Oct 20, 2020 |
| clinicaltrials |
| NCT00478361 | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT00088946 | Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | completed | Phase 2 | 17 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT00462488 | Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ | completed | Phase 2 | 46 | Sesen Bio, Inc.INDUSTRY | 2 | May 12, 2020 | clinicaltrials |
| NCT03534492 | Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)(NEODURVARIB) | completed | Phase 2 | 29 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02028442 | Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients(EVOLVE) | completed | Phase 1 / Phase 2 | 61 | Akamis BioINDUSTRY | 2 | Mar 12, 2020 | clinicaltrials |
| NCT00978250 | A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | completed | Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00722553 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | completed | Phase 2 | 30 | Acrotech Biopharma Inc.INDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
| NCT01589094 | Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT00794950 | Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma(Sutent) | completed | Phase 2 | 43 | University of MichiganOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02141490 | Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT01373294 | Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT02355886 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 / Phase 3 | 25 | University of WashingtonOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01191892 | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | completed | Phase 2 | 82 | Cardiff UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT00595088 | Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer | completed | Phase 2 | 47 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Apr 30, 2019 | clinicaltrials |
| NCT00526656 | Sunitinib in Treating Patients With Locally Advanced Bladder Cancer | completed | Phase 2 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02109328 | Alisertib in Chemotherapy-pretreated Urothelial Cancer | completed | Phase 2 | 22 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT00880334 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | completed | Phase 2 | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00578526 | SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial(SPRUCE) | completed | Phase 2 | 64 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00310011 | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 2 | 71 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00112671 | Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00055601 | Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | completed | Phase 2 | 97 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00963404 | Image-Guided Tumorboost of Bladder Cancer | completed | Phase 1 / Phase 2 | 19 | University of AarhusOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT01259063 | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | completed | Phase 1 / Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT01090466 | Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 1 / Phase 2 | 15 | Cardiff UniversityOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00461851 | Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma | completed | Phase 2 | 17 | Yale UniversityOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT00666562 | Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01938573 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | University of WashingtonOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02655081 | Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy(IMPACT) | completed | Phase 2 | 48 | University of PittsburghOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01687244 | Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | completed | Phase 2 | 40 | FKD Therapies OyINDUSTRY | 0 | Jul 24, 2017 | clinicaltrials |
| NCT00380029 | Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02307487 | Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | completed | Phase 2 | 14 | UroGen Pharma Ltd.INDUSTRY | 1 | Jun 16, 2017 | clinicaltrials |
| NCT01108055 | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | completed | Phase 2 | 43 | Sandy SrinivasOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01828736 | Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma(CVH-CT02) | completed | Phase 2 | 61 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 2 | Feb 6, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00808639 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | completed | Phase 2 | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01454089 | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | completed | Phase 2 | 183 | Achieve Life SciencesINDUSTRY | 7 | Oct 7, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT00406068 | Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer | completed | Phase 2 / Phase 3 | 129 | Bioniche Life Sciences Inc.INDUSTRY | 2 | Jul 28, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 10, 2020source: clinicaltrials